CurrentBlue Cross Blue Shield - New MexicoPolicy CPCPLAB010

Vitamin B12 and Methylmalonic Acid Testing

This policy governs reimbursement criteria for Vitamin B12 and methylmalonic acid laboratory testing for Blue Cross Blue Shield of New Mexico members and applies to providers submitting claims for these services.

Policy Summary

PayerBlue Cross Blue Shield - New Mexico

PolicyVitamin B12 and Methylmalonic Acid Testing

Policy CodePolicy CPCPLAB010

Change TypeRevisions and clarifications (non-material)

Effective DateSeptember 1, 2023

Next Review Date

Key ActionProviders must submit accurate documentation and may be asked to provide additional documentation upon request; claims are subject to review.

SourceLink

POLICY UPDATE CHANGES

Revised criteria to include 'or for those who have been scheduled for' regarding bariatric procedures in risk factor list.

Removed not reimbursable statement on holotranscobalamin testing for screening, testing or confirmation of vitamin B12 deficiency.

Document updated with literature review and other clarifying changes to reimbursement information and references.

Version 1.0policy version

3major reimbursable scenarios

3example codes

2023-07-05last committee approval

Policy Summary

PayerBlue Cross Blue Shield - New Mexico

PolicyVitamin B12 and Methylmalonic Acid Testing

Policy CodePolicy CPCPLAB010

Change TypeRevisions and clarifications (non-material)

Effective DateSeptember 1, 2023

Next Review Date

Key ActionProviders must submit accurate documentation and may be asked to provide additional documentation upon request; claims are subject to review.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Reimbursement Criteria for Testing

Reimbursement criteria

Conditions under which Vitamin B12 and methylmalonic acid testing may be reimbursable.

Diagnostic testing for signs/symptoms

Cutaneous signs: hyperpigmentation, jaundice, vitiligo.
Gastrointestinal sign: glossitis.
Hematologic signs: anemia (macrocytic, megaloblastic), leukopenia, pancytopenia, thrombocytopenia, thrombocytosis.
Neuropsychiatric signs: areflexia; cognitive impairment (including dementia-like symptoms and acute psychosis); gait abnormalities; irritability; loss of proprioception and vibratory sense; olfactory impairment; peripheral neuropathy.

Monitoring during treatment

Vitamin B12 testing for individuals undergoing treatment may be reimbursable when performed no sooner than 3 months after initiation of therapy.

Screening in high-risk individuals

Decreased ileal absorption: Crohn disease; ileal resection; tapeworm infection; having undergone, or scheduled for, bariatric procedures such as Roux-en-Y gastric bypass, sleeve gastrectomy, or biliopancreatic diversion/duodenal switch.
Decreased intrinsic factor: atrophic gastritis; pernicious anemia; post-gastrectomy syndrome.
Transcobalamin II deficiency.
Inadequate B12 intake: alcohol abuse; age >75 years or elderly individuals being evaluated for dementia; vegans or strict vegetarians (including exclusively breastfed infants of vegetarian/vegan mothers); eating disorder.
Prolonged medication use: histamine H2 blocker use for >12 months; metformin use for >4 months; proton pump inhibitor use for >12 months.

Methylmalonic acid testing

In asymptomatic high-risk individuals with low-normal vitamin B12, or when vitamin B12 deficiency is suspected but serum B12 is normal or low-normal, methylmalonic acid testing to confirm deficiency may be reimbursable.
Methylmalonic acid testing may be reimbursable for evaluation of inborn errors of metabolism.

Not reimbursable

Screening for vitamin B12 deficiency in healthy, asymptomatic individuals is not reimbursable.
Homocysteine testing is not reimbursable for confirmation of vitamin B12 deficiency.

Procedure Codes and Timing

Example procedure codes (inclusion does not guarantee coverage)mixed

82607	Vitamin B12; total
83090	Methylmalonic acid
83921	Homocysteine

Post‑treatment testing timing

Post-treatment testing intervalVitamin B12 testing for individuals undergoing treatment may be reimbursable when performed no sooner than 3 months after initiation of therapy.

Applicable testVitamin B12 testing (to monitor response to therapy)

ScopeApplies to testing performed for monitoring during treatment of Vitamin B12 deficiency, per reimbursement criteria.

Documentation and Claim Review

Documentation Required

Submit accurate documentation and support claims upon request

Providers are responsible for submission of accurate documentation of services performed and must submit claims using valid HIPAA-approved code combinations and appropriate industry-standard coding guidelines. Claims are subject to code edit protocols and claim review against benefit coverage, provider contracts, medical policies, clinical payment and coding policies, and coding software logic; upon request, providers must submit any additional documentation.

Submit claims using valid HIPAA-approved code sets (CPT, HCPCS, ICD-10, NDC, DRG) and follow industry coding guidelines.
Claims will be reviewed against plan documents, provider contracts, medical policies, and code edit protocols.
Be prepared to provide additional documentation upon request to support the claim.

Plan Documents

Plan documents (definition and related guidance)

Definition of plan documents'Plan documents' include Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents.

Hierarchy in conflictsIf a conflict exists between this policy and a plan document, the plan document will govern.

Provider responsibilityClaims are subject to review against plan documents, provider contracts, medical policies, and coding policies; providers should submit accurate documentation.